Computation-driven discovery of a next-generation canine monoclonal antibody for canine parvovirus therapy

IF 2.7 2区农林科学 Q3 MICROBIOLOGY

Veterinary microbiology Pub Date : 2026-05-01 Epub Date: 2026-03-06 DOI:10.1016/j.vetmic.2026.110982

Ying Li , Xiaoyu Zhang , Zhihao Wang , Mingqin Lin , Sheng Wang , Chengguang Zhang , Ling Zhao , Jiahui Zou , Hongbo Zhou

{"title":"Computation-driven discovery of a next-generation canine monoclonal antibody for canine parvovirus therapy","authors":"Ying Li , Xiaoyu Zhang , Zhihao Wang , Mingqin Lin , Sheng Wang , Chengguang Zhang , Ling Zhao , Jiahui Zou , Hongbo Zhou","doi":"10.1016/j.vetmic.2026.110982","DOIUrl":null,"url":null,"abstract":"<div><div>Canine parvovirus (CPV) is a highly contagious and lethal pathogen that poses a major threat to canine health. Despite widespread vaccination efforts, CPV remains one of the primary causes of hemorrhagic enteritis and myocarditis. Also, current supportive therapy often fails to work well. Therefore, we urgently need to explore alternative or complementary therapeutic strategies. In this study, by integrating single B-cell sequencing technology with antigen-antibody structure prediction, we successfully screened the canine-derived monoclonal antibody (mAb) E9 against CPV. E9 exhibited high affinity and broad neutralizing activity <em>in vitro</em>, and achieved 80% therapeutic efficacy <em>in vivo</em>. This therapeutic effect highlights E9's great potential as a next-generation CPV biologic. In summary, our study offers a more efficient approach for acquiring neutralizing antibodies and provides a promising strategy for combating CPV.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"316 ","pages":"Article 110982"},"PeriodicalIF":2.7000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113526001136","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Canine parvovirus (CPV) is a highly contagious and lethal pathogen that poses a major threat to canine health. Despite widespread vaccination efforts, CPV remains one of the primary causes of hemorrhagic enteritis and myocarditis. Also, current supportive therapy often fails to work well. Therefore, we urgently need to explore alternative or complementary therapeutic strategies. In this study, by integrating single B-cell sequencing technology with antigen-antibody structure prediction, we successfully screened the canine-derived monoclonal antibody (mAb) E9 against CPV. E9 exhibited high affinity and broad neutralizing activity in vitro, and achieved 80% therapeutic efficacy in vivo. This therapeutic effect highlights E9's great potential as a next-generation CPV biologic. In summary, our study offers a more efficient approach for acquiring neutralizing antibodies and provides a promising strategy for combating CPV.

查看原文本刊更多论文

计算驱动下发现用于犬细小病毒治疗的下一代犬单克隆抗体

犬细小病毒（Canine parvovirus， CPV）是一种具有高度传染性和致死性的病原体，对犬类健康构成重大威胁。尽管广泛的疫苗接种努力，CPV仍然是出血性肠炎和心肌炎的主要原因之一。此外，目前的支持性治疗往往效果不佳。因此，我们迫切需要探索替代或补充治疗策略。本研究将单b细胞测序技术与抗原-抗体结构预测相结合，成功筛选出犬源性抗CPV单克隆抗体（mAb） E9。E9在体外具有高亲和力和广泛的中和活性，体内治疗效果达到80%。这种治疗效果突出了E9作为下一代CPV生物制剂的巨大潜力。总之，我们的研究提供了一种更有效的获得中和抗体的方法，并为对抗CPV提供了一种有前途的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary microbiology 农林科学-兽医学

CiteScore

5.90

自引率

6.10%

发文量

221

审稿时长

52 days

期刊介绍： Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal. Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge. Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.